Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 2/3.

NCT00411385 is registered in ClinicalTrials.gov with Human Genome Sciences Inc. as lead sponsor.

NCT NCT00411385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00411385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 2/3.
Lead sponsor
Human Genome Sciences Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2007
Completion date
October 31, 2008
Enrollment
933 (actual)
Sites
159

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c